Clinical And Evidence - Based Medicine For Hormone Therapy For Endometrial Carcinoma

OBJECTIVE To investigate the clinical effect of hormone therapy on endometrial carcinoma postoperatively, and the effect of hormone therapy on the comprehensive treatment for endometrial carcinoma, to formulate reasonable treatment scheme, to explore the feasibility of hormone therapyMETHODS Retrospective the consecutive cases with endometrial carcinoma from January2005to May2013were documented, including321patients.Statistical processing:application of SPSS19.0statistical analysis software, the count data using X2test, prognosis factor analysis of adjuvant hormone treatment in the endometrial carcinoma postoperative using the single factor analysis, Log-rank test test, P<0.05said the difference was statistically significant, meaningful factors using multi-factors Cox model analysis, P<0.05said the difference is statistically significant.To evaluate the probability of death rate and recurrence rate compared between groups.RESULTS Survival analysis results show that:the Single factor analysis results:Adjuvant hormone treatment more than one year, progesterone receptor (PR), pathologic stage, pathological staging are the important factors that affect hormone therapy efficacy.Excitation multi-factor analysis results:progesterone receptor (PR), pathologic stage, whether hormone use more than one year are independent risk factors influence the curative effect of hormone therapy (P< 0.05). In the adjuvant hormone treatment group compared with control group, the recurrence rate of adjuvant hormone treatment group is lower than the control group, the recurrence rate was statistically difference (P<0.05), the3years,5years survival rate of adjuvant hormone treatment group was higher than the control group,and the3years survival rate>5years survival rate was statistically difference (P<0.05), the hormone group disease-free survival rate was higher than control group, the disease-free survival compared statistically significant difference (P<0.05)。CONCLUSION Hormone therapy for postoperative in endometrial carcinoma had significant effect on the improvement the long-term survival rate of patients. In order to improve the prognosis of patients with endometrial carcinoma,adjuvant hormone therapy should be used routinely in postoperative. OBJECTIVE To systematically evaluate the effects of adjuvant hormone treatment in treating early stage endometrial cancer. METHODS Electronic searches was conducted to identify randomised controlled trials (RCTs) for comparing the effects of surgical, treatment and adjuvant hormone treatment compare with surgical treatment in treating endometrial carcinoma.RESULTS6RCTs were included. Results of Meta-analysis showed:On the risk of death, the total risk of death in the study of the various no statistically significant difference between experimental group and the control group(P=0.33, OR=1.04,95%CI0.88-1.23), Compared with the control group, adjuvant therapy treatment for the patient of early stage endometrial cancer can’t reduce the death rate. On the risk of recurrence, the total risk of recurrence in the study of the various no statistically significant difference between experimental group and the control group(P=0.84,OR=0.80,95%CI0.65-0.98), Compared with the control group, adjuvant hormone treatment for the patient of early stage endometrial cancer can’t reduce the recurrence rate.CONCLUSION Meta analysis Shows that compared with control group, there were no significantly affect in the risk of recurrence and death in Early endometrial carcinoma patients who using the adjuvant hormone treatment after surgery. In early endometrial carcinoma patients who using the adjuvant hormone treatment after surgery,we can’t Say the adjuvant hormone treatment can improve the prognosis of patients.